--- title: "U.S. stock market midday update: Tempus AI up 9%: BTIG raises target price, mRNA vaccine positive catalyst" type: "News" locale: "en" url: "https://longbridge.com/en/news/296646852.md" description: "Tempus AI rose 9.00%; Danaher rose 1.17%, with a transaction volume of USD 750 million; Thermo Fisher Scientific fell 0.11%, with a transaction volume of USD 588 million; Mettler-Toledo rose 0.21%, with a transaction volume of USD 363 million; Agilent Technologies rose 2.51%, with a market value of USD 45.2 billion" datetime: "2026-08-21T19:38:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296646852.md) - [en](https://longbridge.com/en/news/296646852.md) - [zh-HK](https://longbridge.com/zh-HK/news/296646852.md) generator: "portal-rs" --- # U.S. stock market midday update: Tempus AI up 9%: BTIG raises target price, mRNA vaccine positive catalyst **U.S. Stock Market Midday Update** Tempus AI rose 9.00%, with increased trading volume. Based on recent key news: 1. On August 22, BTIG raised Tempus AI's target price to $80, maintaining a buy rating. This move was based on positive Phase III clinical trial results for the mRNA cancer therapy jointly developed by Merck and Moderna, driving the stock price up. Source: Zhitong Finance 2. On August 21, Tempus AI announced the acquisition of Personalis for $1.5 billion, which provides gene sequencing technology to Moderna. The clinical breakthroughs validated the acquisition strategy's value, pushing the stock price up. Source: Wall Street Insight 3. On August 20, Merck and Moderna's personalized mRNA melanoma vaccine achieved positive results in Phase III clinical trials, leading to a collective rally in the biotechnology sector, which boosted Tempus AI's stock price. Source: Jinshi Data, the biotechnology sector rose on the favorable news for mRNA vaccines. **Stocks with High Trading Volume in the Industry** Danaher rose 1.17%, with active trading. Based on recent key news: 1. On August 20, analysts expressed skepticism about Danaher's research performance and capital allocation efficiency, leading funds to flow toward competitors. Analysts pointed out that Danaher performed poorly compared to major life science competitors, prompting funds to shift to peers with clearer growth drivers. 2. On August 20, Danaher issued a company announcement via Business Wire, emphasizing its independent responsibility for information. This announcement may have enhanced market confidence in the company's transparency. 3. On August 19, a MarketBeat analyst report indicated that although Danaher was rated as a moderate buy, top analysts favored five other stocks. This may have affected investor confidence in Danaher. Competition in the life sciences industry has intensified, with significant fund flows. Thermo Fisher Scientific fell 0.11%. Based on recent key news: 1. On August 19, the chairman of Thermo Fisher Scientific met with the mayor of Shanghai to discuss investment and cooperation matters in Shanghai. This move may enhance the company's influence in the Chinese market but failed to immediately boost the stock price. (Shangguan News) 2. On August 19, Thermo Fisher's Senior Vice President Lisa P. Britt sold 11,440 shares of company stock at a price of $613.12 per share. Such executive selling is typically viewed as a negative signal and may put pressure on the stock price. (EDGAR) 3. On August 21, analysts rated Thermo Fisher as "moderate buy," but noted that five other stocks were more attractive. This may lead to weakened investor confidence in Thermo Fisher. The biopharmaceutical industry received policy support in Shanghai Mettler-Toledo rose by 0.21%, with a transaction volume reaching $363 million, and trading volume increased, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks ranked at the top of the industry by market capitalization** Agilent Technologies rose by 2.51%. Based on recent key news: 1. On August 21, Agilent Technologies reported excellent second-quarter earnings, with an operating profit margin of 26.4%, surpassing its competitor Thermo Fisher's 22.8%. Additionally, Agilent's revenue growth rate also exceeded that of Thermo Fisher, despite the latter having more acquisitions to assist. Agilent's stock has risen over 22% in the past month and 33.5% in the past year. 2. On August 19, the YieldMax Magnificent 7 Fund of Option Income ETF systematically collected option premiums from large tech stocks to meet the income needs of its portfolio. This strategy attracted a significant inflow of funds, driving up the related stocks. 3. Recently, analysts are generally optimistic about Agilent Technologies' future performance. Although the first-quarter earnings per share were slightly below expectations, management attributed this to the snowstorm in the U.S. and raised the full-year guidance. The performance in the second quarter further boosted market confidence. Tech stocks have performed strongly recently, with evident capital inflows ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [DHR.US](https://longbridge.com/en/quote/DHR.US.md) - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) - [MTD.US](https://longbridge.com/en/quote/MTD.US.md) - [A.US](https://longbridge.com/en/quote/A.US.md) ## Related News & Research - [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md) - [Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock](https://longbridge.com/en/news/296562025.md) - [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md) - [The push for AI watermarks is spawning a new wave of tools to remove them](https://longbridge.com/en/news/296262434.md) - [Originalis AI Founding Engineer Ujjwal Jain Unveils AI System Processing Over 645,000 VC Email Threads](https://longbridge.com/en/news/296065185.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**